Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
June 11, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the...
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
June 04, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts - - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
June 04, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset - - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study...
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
June 02, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing...
Adaptimmune Reports First Quarter 2018 Financial Results and Business Update
May 09, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO - - Guidance confirmed, funded...
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
April 25, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the...
Adaptimmune Announces Changes to Board of Directors
April 12, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, U.K., April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned...
Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
April 06, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing...
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
March 15, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing...